Andromeda (ASX:ADN) share price slides 8% despite positive updates

The Andromeda share price is struggling to find headway despite a series of project updates

| More on:
Man in mining or construction uniform sits on the floor with worried look on face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Andromeda Metals Ltd (ASX: ADN) share price is losing ground today despite a series of updates for its Great White Kaolin project.

The Andromeda share price is down 8% trading at 20.5 cents at the time of writing.

What did Andromeda announce?

Offtake agreements

Earlier this month, the Andromeda share price surged as much as 27% to 27.5 cents following a significant binding offtake agreement for the supply of kaolin product.

The offtake agreement secured a much higher price to what was used in the company's pre-feasibility study, of A$700/tonne for ceramic grade material.

Additionally, the offtake agreement introduces a second product stream of ultra-bright, high-purity kaolin product, known as "Great White PRM'. The company says this will provide the benefit of product diversification and assist in managing offtake market risk.

Today's announcement advises that Conrad Partners, a commodity marketing agency, has engaged with high end ceramic users in China to secure additional offtake agreements for Andromeda. Some potential customers have previously signed letters of intent for Great White products. Conrad aims to translate potential interest into binding offtake agreements.

Additionally, Andromeda is in advanced discussion with potential customers located in Europe, the Middle East and other parts of Asia for the Great White refined halloysite-kaolin product.

Definitive feasibility study update

Andromeda advises that its definitive feasibility study (DFS) is "well advanced" but has only focused on the production of Great White CRM for the ceramics market.

The recent binding offtake agreement for Great White PRM for the coatings and polymer market will need to be incorporated into the DFS.

Mining lease application

Andromeda previously lodged a mining please application with the South Australian Department for Energy and Mining (DEM) on 25 February 2021.

The company forecasts the receipt of the mining please approval by mid-2022 in line with DFS and bankable feasibility study (BFS) completion.

Other updates

Andromeda is testing the potential use of its halloysite-kaolin product as a rheology modifier product for the concrete industry. The company has successfully lodged a patent and is currently undertaking additional test work. It said the addition of halloysite-kaolin to concrete could potentially reduce concrete costs, lower carbon footprint and improve performance for concrete suppliers.

The potential concrete application is currently in a testing phase and product marketing has yet to be performed. The company advised that this is unlikely to be included in the DFS.

Andromeda entered into a memorandum of understanding with AEM to use its patented process to make high purity alumina (HPA) using kaolin back in May.

Today's announcement advised that HPA studies are progressing and samples have been provided to AEM for testing.

The Andromeda share price in 2021

Despite today's positive list of updates, the Andromeda share price has slipped 6.67% to 21 cents today.

It's possible today's sharp fall could be exacerbated by the 1.8% drop in the S&P/ASX 200 Index (ASX: XJO).

The Andromeda share price is down 32% this year, with a year-to-date low of 16 cents.

Kerry Sun has no position in any of the stocks mentioned.  The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »